Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...
Hosted on MSN16h
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy treatment. ... Read More The post Health Check: Alterity angles for fast-track FDA ...
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...
Zevra Therapeutics To Present At The 21St Annual Worldsymposium™
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .
Hosted on MSN17h
Phase III Trials: It’s crunch time for these ASX health stocks
Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...
The 10 strangest rumours about The Beatles
Psychedelia sent the rumour mill into overdrive concerning The Beatles - here we count down 10 of the strangest conspiracies ...
Effective Pharma Marketing Authorisation Application Training Course (ONLINE EVENT: February 5-6, 2025)
The "Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application Training Course" conference has been added to ResearchAndMarkets.com's offering. The Common ...